Avalere’s Research Team to Present Comparative Effectiveness Research at Cystic Fibrosis Conference
Summary
Results from a new Avalere study will be presented Thursday, October 27, at the 30th Annual North American Cystic Fibrosis Conference in Orlando, Florida.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.
Drs. Karl Kilgore, Alexis Parente, and Seung Kim, members of Avalere’s Advanced Analytics team, will be co-presenting a study titled “Assessing the Impact of a Pharmacy-Based Therapy Management Program on Adherence and Healthcare Utilization in Cystic Fibrosis.” The poster, authored by Dr. Heather Kirkham, director of Health Analytics, Research, & Reporting at Walgreens, and coauthored with Dr. Gregory Sawicki, Boston Children’s Hospital and others, will be presented on Thursday, October 27, 2016, 11:15AM–1:45PM. The study examined the effectiveness of a pharmacy-based comprehensive therapy management program—the Walgreens Connected Care® CF (Cystic Fibrosis) program—compared to a matched sample of control patients. Patients in the intervention group were found to have significantly higher medication adherence, fewer ER visits and lower ER costs. Other outcomes (e.g., total medical costs, hospitalizations, and pulmonary exacerbations) all favored the program sample but did not achieve statistical significance.
The study was supported by data from Inovalon’s Medical Outcomes Research for Effectiveness and Economics (MORE2) Registry®.
Related Content
